Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Director | June 18, 2026 | June 23, 2026 |
| Twist Bioscience CorpTWST · Entity 3619 | Director · Chief Executive Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 24,852 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 24,852 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,248 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 4,248 · Balance 4,248 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Twist Bioscience Corp
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 562,760 |
Ending reported balance
After 2026-10-05 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-10-05 · Sale · Disposed 1,840 · Balance 565,468 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 2 · 2026-10-05 · Sale · Disposed 481 · Balance 564,987 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-10-05 · Sale · Disposed 1,017 · Balance 563,970 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 4 · 2026-10-05 · Sale · Disposed 432 · Balance 563,538 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 5 · 2026-10-05 · Sale · Disposed 290 · Balance 563,248 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 6 · 2026-10-05 · Sale · Disposed 297 · Balance 562,951 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 7 · 2026-10-05 · Sale · Disposed 146 · Balance 562,805 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 8 · 2026-10-05 · Sale · Disposed 45 · Balance 562,760 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.33 · Expires 2029-10-23 | Direct | 131,290 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 131,290 F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.85 · Expires 2030-08-31 | Direct | 64,950 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 64,950 F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2023 Filed Jul 25, 2023 20:17 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantStock Option (Right to Buy) · Derivative | 8,816 | $0.00 Strike: $7.89 | $0.00 |
DisclosureSEC source: 0001209191-23-043296 · doc4.xml · derivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,816 Underlying: Class A Common Stock · 8,816 shares Expires 2033-07-20 F1 · derivative.exercise_date: The stock option shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,122 | $20.46 | $22,956.12 |
DisclosureSEC source: 0001214659-23-009243 · marketforms-62020.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,470 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,748 | $18.31 | $32,005.88 |
DisclosureSEC source: 0001214659-23-008704 · marketforms-61898.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,592 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| May 19, 2023 Filed May 23, 2023 20:10 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,754 | $13.03 | $35,884.62 |
DisclosureSEC source: 0001214659-23-007730 · marketforms-61598.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,340 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| May 04, 2023 Filed May 8, 2023 20:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,360 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-23-006627 · marketforms-61405.xml · derivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,360 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 04, 2023 Filed May 8, 2023 20:00 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 24,360 | $5.95 | $144,942.00 |
DisclosureSEC source: 0001214659-23-006627 · marketforms-61405.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 4, 2023 20:07 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 45,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027320 · doc4.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 45,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The underlying shares shall vest on the earlier of the (a) date of the 2023 annual meeting of the Issuer's stockholders, and (b) first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer on the applicable vesting date. F2 · derivative.expiration_date: The underlying shares shall vest on the earlier of the (a) date of the 2023 annual meeting of the Issuer's stockholders, and (b) first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer on the applicable vesting date. Read SEC document |
| May 02, 2023 Filed May 4, 2023 20:07 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 45,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027320 · doc4.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2023 Filed Apr 26, 2023 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 898 | $13.63 | $12,239.74 |
DisclosureSEC source: 0001214659-23-006001 · marketforms-61312.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,734 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,121 | $15.08 | $16,904.68 |
DisclosureSEC source: 0001214659-23-004905 · marketforms-61137.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,632 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:02 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,748 | $16.51 | $28,859.48 |
DisclosureSEC source: 0001214659-23-004054 · marketforms-60924.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,753 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,741 | $22.52 | $61,727.32 |
DisclosureSEC source: 0001214659-23-002909 · marketforms-59582.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,868 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 980 | $28.74 | $28,165.20 |
DisclosureSEC source: 0001214659-23-001160 · marketforms-58286.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,609 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 490 | $23.81 | $11,666.90 |
DisclosureSEC source: 0001214659-23-000268 · marketforms-57990.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,589 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 628 | $23.81 | $14,952.68 |
DisclosureSEC source: 0001214659-23-000268 · marketforms-57990.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,079 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 59,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-015184 · marketforms-57917.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,707 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of December 19, 2022 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:28 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,762 | $24.81 | $68,525.22 |
DisclosureSEC source: 0001214659-22-014114 · marketforms-57530.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,949 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 923 | $29.08 | $26,840.84 |
DisclosureSEC source: 0001214659-22-012658 · marketforms-57359.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,711 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 486 | $35.24 | $17,126.64 |
DisclosureSEC source: 0001214659-22-011986 · marketforms-57256.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,634 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:30 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 627 | $35.24 | $22,095.48 |
DisclosureSEC source: 0001214659-22-011986 · marketforms-57256.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,120 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,812 | $42.81 | $120,381.72 |
DisclosureSEC source: 0001214659-22-010499 · marketforms-56968.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,747 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| July 22, 2022 Filed Jul 26, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 913 | $43.52 | $39,733.76 |
DisclosureSEC source: 0001214659-22-009197 · marketforms-56707.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,559 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,111 | $37.08 | $41,195.88 |
DisclosureSEC source: 0001214659-22-008652 · marketforms-56627.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,472 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,783 | $36.99 | $102,943.17 |
DisclosureSEC source: 0001214659-22-007386 · marketforms-56319.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,583 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| May 02, 2022 Filed May 5, 2022 00:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 45,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-027284 · doc4.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,454 Underlying: Class A Common Stock · 45,454 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F1 · derivative.expiration_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| May 02, 2022 Filed May 5, 2022 00:27 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantStock Option (Right to Buy) · Derivative | 78,914 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001209191-22-027284 · doc4.xml · derivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,914 Underlying: Class A Common Stock · 78,914 shares Expires 2032-05-01 F1 · derivative.exercise_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| May 02, 2022 Filed May 6, 2022 22:58 UTC Amendment | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantStock Option · Derivative | 78,914 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-22-027688 · doc4a.xml · derivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,914 Underlying: Class A Common Stock · 78,914 shares Expires 2032-05-01 F1 · derivative.exercise_price: This Form 4 amendment has been filed solely to correct the exercise price of a previously issued stock option to purchase shares of Class A Common Stock of the Issuer reported in a Form 4 filed on May 4, 2022 (the "Form 4"). The exercise price was inadvertently stated as $2.155 in the Form 4. The exercise price should have been stated as $2.20 in the Form 4. F2 · derivative.exercise_date: The underlying shares shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
| April 27, 2022 Filed May 13, 2022 00:21 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 12,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028688 · doc4.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 12,836 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the date of the next annual meeting of the Company's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the non-employee director continues to provide services to the Company through such vesting date. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the date of the next annual meeting of the Company's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the non-employee director continues to provide services to the Company through such vesting date. Read SEC document |
| April 27, 2022 Filed May 13, 2022 00:21 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 12,836 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028688 · doc4.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 22, 2022 Filed Apr 26, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 923 | $34.21 | $31,575.83 |
DisclosureSEC source: 0001214659-22-005840 · marketforms-56028.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,366 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,108 | $52.91 | $58,624.28 |
DisclosureSEC source: 0001214659-22-004863 · marketforms-55956.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,289 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c) Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 2,837 | $53.21 | $150,956.77 |
DisclosureSEC source: 0001214659-22-003086 · marketforms-55524.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,165 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:46 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 1,008 | $55.87 | $56,316.96 |
DisclosureSEC source: 0001214659-22-001143 · marketforms-55145.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,002 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 286 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-22-000946 · marketforms-55096.xml · derivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,879 Underlying: Common Stock · 286 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 579 | $77.39 | $44,808.81 |
DisclosureSEC source: 0001214659-22-000946 · marketforms-55096.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,010 F3 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 286 | $60.03 | $17,169.09 |
DisclosureSEC source: 0001214659-22-000946 · marketforms-55096.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,589 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $60.00 to $60.13 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 286 | $8.82 | $2,522.52 |
DisclosureSEC source: 0001214659-22-000946 · marketforms-55096.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Tax withholdingCommon Stock | 700 | $77.39 | $54,173.00 |
DisclosureSEC source: 0001214659-22-000239 · marketforms-54863.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,589 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,348 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-22-000239 · marketforms-54863.xml · derivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,165 Underlying: Common Stock · 11,348 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,533 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-22-000239 · marketforms-54863.xml · derivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,360 Underlying: Common Stock · 11,533 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 11,348 | $8.82 | $100,089.36 |
DisclosureSEC source: 0001214659-22-000239 · marketforms-54863.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 11,533 | $5.95 | $68,621.35 |
DisclosureSEC source: 0001214659-22-000239 · marketforms-54863.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 16,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-013757 · marketforms-54817.xml · nonDerivative · entry 7 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,408 F6 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of October 1, 2021, for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 100 | $83.80 | $8,380.00 |
DisclosureSEC source: 0001214659-21-013757 · marketforms-54817.xml · nonDerivative · entry 6 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,563 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 200 | $82.43 | $16,486.00 |
DisclosureSEC source: 0001214659-21-013757 · marketforms-54817.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,663 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $82.40 to $82.46 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,100 | $81.83 | $90,013.44 |
DisclosureSEC source: 0001214659-21-013757 · marketforms-54817.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,863 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $81.40 to $82.12 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,938 | $80.86 | $156,705.52 |
DisclosureSEC source: 0001214659-21-013757 · marketforms-54817.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,963 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $80.395 to $81.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,962 | $80.12 | $157,194.66 |
DisclosureSEC source: 0001214659-21-013757 · marketforms-54817.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,901 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 28, 2021. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $79.35 to $80.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 22, 2021 Filed Dec 29, 2021 21:35 UTC | Twist Bioscience Corp TWST · Entity 3619 | GiftCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-013757 · marketforms-54817.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,863 Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:57 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,960 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001214659-21-012990 · marketforms-54594.xml · derivative · entry 8 Leproust Emily M. · CIK 0001753655 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,893 Underlying: Common Stock · 6,960 shares Expires 2025-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.